T2 Biosystems, Inc. (TTOO) 

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Show less

Over the last 12 months, insiders at T2 Biosystems, Inc. have bought $0 and sold $12.03M worth of T2 Biosystems, Inc. stock.

On average, over the past 5 years, insiders at T2 Biosystems, Inc. have bought $47,937 and sold $2.48M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 12,952 shares for transaction amount of $6,476 was made by Barclay Alec (Chief Operations Officer) on 2022‑04‑08.